Gérard Sanderink

1.1k total citations
17 papers, 866 citations indexed

About

Gérard Sanderink is a scholar working on Oncology, Molecular Biology and Pharmacology. According to data from OpenAlex, Gérard Sanderink has authored 17 papers receiving a total of 866 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Oncology, 5 papers in Molecular Biology and 4 papers in Pharmacology. Recurrent topics in Gérard Sanderink's work include Cancer Treatment and Pharmacology (6 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Atrial Fibrillation Management and Outcomes (3 papers). Gérard Sanderink is often cited by papers focused on Cancer Treatment and Pharmacology (6 papers), Pharmacogenetics and Drug Metabolism (4 papers) and Atrial Fibrillation Management and Outcomes (3 papers). Gérard Sanderink collaborates with scholars based in France, United Kingdom and United States. Gérard Sanderink's co-authors include Yves Artur, Gérard Siest, M Martinet, René Bruno, Georges de Sousa, Roger Rahmani, Charlotte Gaillard, Richard C. Becker, Jean‐Michel Scherrmann and Frederick A. Spencer and has published in prestigious journals such as Cancer Research, Journal of Pharmacology and Experimental Therapeutics and British Journal of Pharmacology.

In The Last Decade

Gérard Sanderink

17 papers receiving 825 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gérard Sanderink France 11 412 243 174 160 142 17 866
Christina R. Chow United States 15 150 0.4× 428 1.8× 85 0.5× 25 0.2× 61 0.4× 29 773
Giridhar Tirucherai United States 17 67 0.2× 416 1.7× 338 1.9× 199 1.2× 39 0.3× 41 1.3k
Celeste B. Burness New Zealand 17 106 0.3× 200 0.8× 65 0.4× 46 0.3× 20 0.1× 29 727
Toshihiro Oguma Japan 22 203 0.5× 398 1.6× 475 2.7× 328 2.0× 46 0.3× 34 1.7k
Jiro Seki Japan 19 76 0.2× 351 1.4× 232 1.3× 36 0.2× 31 0.2× 66 1.2k
Girolamo Del Monte Italy 16 365 0.9× 185 0.8× 43 0.2× 37 0.2× 25 0.2× 20 779
Katherine E. Harris United States 20 204 0.5× 217 0.9× 1.1k 6.5× 45 0.3× 15 0.1× 35 1.7k
Jean‐Marc Herbert France 18 94 0.2× 403 1.7× 426 2.4× 182 1.1× 12 0.1× 37 1.2k
Nils‐Erik Huseby Norway 17 71 0.2× 241 1.0× 83 0.5× 66 0.4× 40 0.3× 36 888
J. Eileen Bird United States 21 160 0.4× 305 1.3× 229 1.3× 22 0.1× 12 0.1× 38 1.0k

Countries citing papers authored by Gérard Sanderink

Since Specialization
Citations

This map shows the geographic impact of Gérard Sanderink's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gérard Sanderink with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gérard Sanderink more than expected).

Fields of papers citing papers by Gérard Sanderink

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gérard Sanderink. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gérard Sanderink. The network helps show where Gérard Sanderink may publish in the future.

Co-authorship network of co-authors of Gérard Sanderink

This figure shows the co-authorship network connecting the top 25 collaborators of Gérard Sanderink. A scholar is included among the top collaborators of Gérard Sanderink based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gérard Sanderink. Gérard Sanderink is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Chuang, Wei‐Lien, et al.. (2019). Galactosylsphingosine does not interfere with the quantitation of plasma glucosylsphingosine levels in Gaucher patients. Clinica Chimica Acta. 494. 48–51. 9 indexed citations
2.
Sémiond, Dorothée, et al.. (2012). Abstract 749: A Phase I, open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors. Cancer Research. 72(8_Supplement). 749–749. 2 indexed citations
3.
Veyrat‐Follet, Christine, Nicole Vivier, C. Dubruc, et al.. (2011). A mechanism‐based model for the population pharmacokinetics of free and bound aflibercept in healthy subjects. British Journal of Clinical Pharmacology. 72(3). 402–414. 16 indexed citations
4.
Paty, Isabelle, et al.. (2010). Reversibility of the anti‐FXa activity of idrabiotaparinux (biotinylated idraparinux) by intravenous avidin infusion. Journal of Thrombosis and Haemostasis. 8(4). 722–729. 44 indexed citations
5.
Veyrat‐Follet, Christine, et al.. (2009). The pharmacokinetics of idraparinux, a long-acting indirect factor Xa inhibitor: population pharmacokinetic analysis from Phase III clinical trials. Journal of Thrombosis and Haemostasis. 7(4). 559–565. 30 indexed citations
6.
Cisternino, Salvatore, et al.. (2003). Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P‐glycoprotein at the blood–brain barrier in mice and rats. British Journal of Pharmacology. 138(7). 1367–1375. 93 indexed citations
7.
Becker, Richard C., Frederick A. Spencer, Michael Gibson, et al.. (2002). Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes. American Heart Journal. 143(5). 753–759. 130 indexed citations
8.
Sanderink, Gérard, Bruno Bournique, Jeffrey Stevens, Marianne Petry, & M Martinet. (1997). Involvement of Human CYP1A Isoenzymes in the Metabolism and Drug Interactions of Riluzole In Vitro. Journal of Pharmacology and Experimental Therapeutics. 282(3). 1465–1472. 67 indexed citations
9.
Sanderink, Gérard, et al.. (1996). Hepatic biotransformation of docetaxel (Taxotere) in vitro: involvement of the CYP3A subfamily in humans.. PubMed. 56(6). 1296–302. 199 indexed citations
10.
Lokiec, François, et al.. (1996). Irinotecan (CPT-11) metabolites in human bile and urine.. PubMed. 2(12). 1943–9. 47 indexed citations
11.
Bruno, René & Gérard Sanderink. (1993). Pharmacokinetics and metabolism of Taxotere (docetaxel).. PubMed. 17. 305–13. 68 indexed citations
12.
Bruno, René & Gérard Sanderink. (1993). Pharmacokinetics and metabolism of taxotere. 7 indexed citations
13.
Sanderink, Gérard, Yves Artur, & Gérard Siest. (1988). Human Aminopeptidases: A Review of the Literature. Clinical Chemistry and Laboratory Medicine (CCLM). 26(12). 795–807. 127 indexed citations
14.
Sanderink, Gérard, Yves Artur, F Schiele, R Guéguen, & Gérard Siest. (1988). Alanine aminopeptidase in serum: biological variations and reference limits.. Clinical Chemistry. 34(7). 1422–1426. 19 indexed citations
15.
Sanderink, Gérard, et al.. (1988). Micro-scale two-dimensional electrophoresis of alkaline phosphatase from serum.. Clinical Chemistry. 34(4). 730–735. 4 indexed citations
16.
Artur, Yves, Gérard Sanderink, & I Maire. (1987). [Macroenzymes in human plasma. 2. Macrogamma-glutamyltransferase, macroalanine aminopeptidase, macroalkaline phosphatase, macroaminotransferases and other macroenzymes].. PubMed. 45(3). 277–84. 1 indexed citations
17.
Roelofsen, B., Gérard Sanderink, Esther Middelkoop, R.J. Hamer, & Jos A.F. Op den Kamp. (1984). Murine erythrocytes contain high levels of lysophospholipase activity. Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism. 792(1). 99–102. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Christina R. Chow Breakdown of academic impact, for papers by Giridhar Tirucherai Breakdown of academic impact, for papers by Celeste B. Burness Breakdown of academic impact, for papers by Toshihiro Oguma Breakdown of academic impact, for papers by Jiro Seki Breakdown of academic impact, for papers by Girolamo Del Monte Breakdown of academic impact, for papers by Katherine E. Harris Breakdown of academic impact, for papers by Jean‐Marc Herbert Breakdown of academic impact, for papers by Nils‐Erik Huseby Breakdown of academic impact, for papers by J. Eileen Bird
Rankless by CCL
2026